As a result of the new customer implementation and other positive business developments, CorMedix (CRMD) is increasing its second quarter net sales guidance from the previously communicated $31M to a range of $35M to $40M.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks